We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Research Makes Flu Virus Visible to Naked Eye

By LabMedica International staff writers
Posted on 16 May 2017
Researchers have discovered a way to make influenza visible to the naked eye by engineering fluorescent dye molecules to target a specific enzyme of the virus. More...
The team was able to develop a prototype test kit that detects influenza in samples using a handheld lamp or blue laser pointer, and that even helps determine if a given antiviral therapy will likely be effective.

The scientists, from University of Notre Dame, created a new method to detect neuraminidase, which is located on the surface of the virus. They began by designing a dye molecule to emit red fluorescent light when it interacts with the neuraminidase. They then used test samples that mimicked that of an infected patient, and spiked the samples with neuraminidase that had been purified from the virus. Emission of red fluorescent light from a sample is a positive indication of the influenza virus, blue signals a negative result.

While still a prototype, with optimization the diagnostic could potentially be developed for use in point-of-care clinics or the home environment for a rapid, easy to interpret test for the presence of influenza.

The same process also allowed them to determine which of two approved antiviral drugs would be a better treatment option for the individual patient.

Following validation of enzyme recognition, the team tested the dye with two antiviral drugs used to treat influenza (Zanamivir, also known as Relenza, and Oseltamivir, known widely as Tamiflu). Both antivirals are neuraminidase inhibitors. Antiviral drug was added to samples containing dye and neuraminidase. Upon illumination, red fluorescence indicated the enzyme was still active, whereas blue indicated the drug failed to inhibit the enzyme. For patient samples, blue fluorescence would indicate the neuraminidase activity had been blocked, presenting an effective treatment option.

“Viral cultures are the gold standard for diagnosis of influenza but take several days to develop. By targeting an enzyme inherent to the virus and identifying its presence in a sample, we can make a rapid determination of the influenza in a patient for an efficient and immediate diagnostic that would improve patient treatment and reduce overuse of antivirals,” said study leader Bradley Smith, professor at Notre Dame.

The study, by Liu W et al, was published April 20, 2017, in the Journal of the American Chemical Society.


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.